**Diagnosis and Differential Diagnosis**

[Multiple sclerosis: renaming the notorious and historical diagnosis?](https://www.ncbi.nlm.nih.gov/pubmed/32072373)

Abdulsalam AJ, Özçakar L.

Neurol Sci. 2020 Feb 18. doi: 10.1007/s10072-020-04291-y. [Epub ahead of print] No abstract available.

[Primary progressive multiple sclerosis to be treated with ocrelizumab: a mistaken case of cobalamin deficiency.](https://www.ncbi.nlm.nih.gov/pubmed/31092497)

Feldman S, Aljarallah S, Saidha S.

BMJ Case Rep. 2019 May 14;12(5). pii: e229080. doi: 10.1136/bcr-2018-229080.

[Phase-synchrony evaluation of EEG signals for Multiple Sclerosis diagnosis based on bivariate empirical mode decomposition during a visual task.](https://www.ncbi.nlm.nih.gov/pubmed/32072973)

Raeisi K, Mohebbi M, Khazaei M, Seraji M, Yoonessi A.

Comput Biol Med. 2020 Feb;117:103596. doi: 10.1016/j.compbiomed.2019.103596. Epub 2019 Dec 30.

[Complete horizontal gaze palsy due to bilateral paramedian pontine reticular formation involvement as a presentation of multiple sclerosis: a case report.](https://www.ncbi.nlm.nih.gov/pubmed/31656191)

Akhavan Sigari A, Etemadifar M, Salari M.

BMC Neurol. 2019 Oct 27;19(1):254. doi: 10.1186/s12883-019-1494-0.

[Recurrent ischemic stroke in a case of Takayasu's arteritis, mimicking multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31749937)

Sasannejad P, Verdipour M, Asadi M, Ahmadi H.

Iran J Neurol. 2019 Jul 6;18(3):145-147. No abstract available.

**Epidemiology and Risk Factors**

[History of Multiple Sclerosis in Iran.](https://www.ncbi.nlm.nih.gov/pubmed/32126791)

Moghadasi AN.

Arch Iran Med. 2020 Mar 1;23(3):211-215.

[The relationship of indoor radon gas concentration with multiple sclerosis: a case-control study.](https://www.ncbi.nlm.nih.gov/pubmed/32124296)

Abaszadeh Fathabadi Z, Ehrampoush MH, Mirzaei M, Mokhtari M, Nadi Sakhvidi M, Rahimdel A, Dehghani Tafti A, Fallah Yakhdani M, Atefi A, Eslami H, Ebrahimi AA.

Environ Sci Pollut Res Int. 2020 Mar 2. doi: 10.1007/s11356-020-08147-y. [Epub ahead of print]

[Urbanization theory and socioeconomic changeover of multiple sclerosis in Iran.](https://www.ncbi.nlm.nih.gov/pubmed/31433856)

Zarghami A, Nourmohammadi ST, Hojjati SMM.

Acta Neurol Scand. 2020 Mar;141(3):256. doi: 10.1111/ane.13159. Epub 2019 Sep 9. No abstract available.

[A matched case-control study of risk factors associated with multiple sclerosis in Kuwait.](https://www.ncbi.nlm.nih.gov/pubmed/32085743)

El-Muzaini H, Akhtar S, Alroughani R.

BMC Neurol. 2020 Feb 21;20(1):64. doi: 10.1186/s12883-020-01635-1.

[Does the multiple sclerosis (MS) map need to change again? An update of MS prevalence in Mazandaran province of Iran in 2018.](https://www.ncbi.nlm.nih.gov/pubmed/32050931)

Baghbanian SM, Cheraghmakani H, HabibiSaravi R, Azar A, Ghasemihamedani F.

BMC Neurol. 2020 Feb 12;20(1):52. doi: 10.1186/s12883-020-1618-6.

[Rising prevalence of multiple sclerosis in Saudi Arabia, a descriptive study.](https://www.ncbi.nlm.nih.gov/pubmed/32035478)

AlJumah M, Bunyan R, Al Otaibi H, Al Towaijri G, Karim A, Al Malik Y, Kalakatawi M, Alrajeh S, Al Mejally M, Algahtani H, Almubarak A, Cupler E, Alawi S, Qureshi S, Nahrir S, Almalki A, Alhazzani A, Althubaiti I, Alzahrani N, Mohamednour E, Saeedi J, Ishak S, Almudaiheem H, El-Metwally A, Al-Jedai A.

BMC Neurol. 2020 Feb 8;20(1):49. doi: 10.1186/s12883-020-1629-3.

[The higher prevalence of multiple sclerosis among Iranian Georgians; new clues to the role of genetic factors.](https://www.ncbi.nlm.nih.gov/pubmed/31182312)

Etemadifar M, Ghourchian S, Sabeti F, Akbari M, Etemadifar F, Salari M.

Rev Neurol (Paris). 2020 Jan - Feb;176(1-2):113-117. doi: 10.1016/j.neurol.2019.04.004. Epub 2019 Jun 8.

[Awareness of patients with multiple sclerosis in Saudi Arabia regarding the relationship between smoking and multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31982900)

Kashoo FZ, Alqahtani M, Ahmad F.

Neurosciences (Riyadh). 2020 Jan;25(1):73. doi: 10.17712/nsj.2020.1.20190105. No abstract available.

[Environmental Influencers, MicroRNA, and Multiple Sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/32009827)

Mohammed EM.

J Cent Nerv Syst Dis. 2020 Jan 20;12:1179573519894955.

[Epidemiology and phenotypes of multiple sclerosis in the Middle East North Africa (MENA) region.](https://www.ncbi.nlm.nih.gov/pubmed/31984137)

Yamout BI, Assaad W, Tamim H, Mrabet S, Goueider R.

Mult Scler J Exp Transl Clin. 2020 Jan 14;6(1):2055217319841881. doi: 10.1177/2055217319841881. eCollection 2020

[Incidence and prevalence of multiple sclerosis in persian gulf area: A systematic review and meta-analysis.](https://www.ncbi.nlm.nih.gov/pubmed/31991397)

Etemadifar M, Nikanpour Y, Neshatfar A, Mansourian M, Fitzgerald S.

Mult Scler Relat Disord. 2020 Jan 21;40:101959. doi: 10.1016/j.msard.2020.101959. [Epub ahead of print] Review.

[Prevalence, dimensions, and predictor factors of sexual dysfunction in women of Iran Multiple Sclerosis Society: a cross-sectional study.](https://www.ncbi.nlm.nih.gov/pubmed/31897948)

Ghasemi V, Simbar M, Ozgoli G, Nabavi SM, Alavi Majd H.

Neurol Sci. 2020 Jan 2. doi: 10.1007/s10072-019-04222-6. [Epub ahead of print]

 [Analysis of brain functional connectivity network in MS patients constructed by modular structure of sparse weights from cognitive task-related fMRI.](https://www.ncbi.nlm.nih.gov/pubmed/31452057)

Miri Ashtiani SN, Behnam H, Daliri MR, Hossein-Zadeh GA, Mehrpour M.

Australas Phys Eng Sci Med. 2019 Dec;42(4):921-938. doi: 10.1007/s13246-019-00790-1. Epub 2019 Aug 26.

[Association between vitamin D receptor (VDR) polymorphisms and the risk of multiple sclerosis (MS): an updated meta-analysis.](https://www.ncbi.nlm.nih.gov/pubmed/31878897)

Imani D, Razi B, Motallebnezhad M, Rezaei R.

BMC Neurol. 2019 Dec 26;19(1):339. doi: 10.1186/s12883-019-1577-y.

[The protective effect of Helicobacter Pylori infection on the susceptibility of multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31610314)

Ranjbar R, Karampoor S, Jalilian FA.

J Neuroimmunol. 2019 Dec 15;337:577069. doi: 10.1016/j.jneuroim.2019.577069. Epub 2019 Sep 14.

[Letter to the Editor: Lack of Attention to Epidemiological Study of Neuromyelitis Optica Spectrum Disorder Compared with that of Multiple Sclerosis in Iran.](https://www.ncbi.nlm.nih.gov/pubmed/31889934)

Moghadasi AN.

Int J MS Care. 2019 Nov-Dec;21(6):281. doi: 10.7224/1537-2073.2019-043. No abstract available.

[Age at menarche and risk of multiple sclerosis (MS): a systematic review and meta-analysis.](https://www.ncbi.nlm.nih.gov/pubmed/31727014)

Azimi A, Hanaei S, Sahraian MA, Mohammadifar M, Ramagopalan SV, Ghajarzadeh M.

BMC Neurol. 2019 Nov 14;19(1):286. doi: 10.1186/s12883-019-1473-5.

[Bifidobacteria: A probable missing puzzle piece in the pathogenesis of multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31487552)

Toghi M, Bitarafan S, Kasmaei HD, Ghafouri-Fard S.

Mult Scler Relat Disord. 2019 Nov;36:101378. doi: 10.1016/j.msard.2019.101378. Epub 2019 Aug 28. Review.

[Do socioeconomic factors affect the prevalence of multiple sclerosis in Iran?](https://www.ncbi.nlm.nih.gov/pubmed/31291697)

Pakdel M, Karin Hedström A, Bidkhori M, Hadei M, Kazemi Moghaddam V, Sarmadi M, Zohdi S, Marufi N.

Acta Neurol Scand. 2019 Nov;140(5):328-335. doi: 10.1111/ane.13148. Epub 2019 Jul 31.

[Incidence of multiple sclerosis in Iran: a nationwide, population-based study.](https://www.ncbi.nlm.nih.gov/pubmed/31476710)

Hosseinzadeh A, Baneshi MR, Sedighi B, Kermanchi J, Haghdoost AA.

Public Health. 2019 Oct;175:138-144. doi: 10.1016/j.puhe.2019.07.013. Epub 2019 Aug 30.

[Multiple Sclerosis in Tehran: Rising Prevalence alongside Stabilizing Incidence - True Increase or Enhanced Diagnosis?](https://www.ncbi.nlm.nih.gov/pubmed/31679345)

Mohebi F, Eskandarieh S, Mansournia MA, Mohajer B, Sahraian MA.

Arch Iran Med. 2019 Aug 1;22(8):429-434.

[Multiple sclerosis national registry system in Iran: Validity and reliability of a minimum data set.](https://www.ncbi.nlm.nih.gov/pubmed/31203146)

Shahin S, Eskandarieh S, Moghadasi AN, Razazian N, Baghbanian SM, Ashtari F, Bayati A, Manouchehrinia A, Beiki O, Mohebi F, Dezfuli MM, Sahraian MA.

Mult Scler Relat Disord. 2019 Aug;33:158-161. doi: 10.1016/j.msard.2019.06.009. Epub 2019 Jun 9.

[Seasonal variations of 25-OH vitamin D serum levels in Multiple Sclerosis patients with relapse using MRI.](https://www.ncbi.nlm.nih.gov/pubmed/31579482)

Sistani SS, Moghtaderi A, Dashipoor AR, Ghaffarpoor M, Ghahderijani BH.

Eur J Transl Myol. 2019 Aug 8;29(3):8361. doi: 10.4081/ejtm.2019.8361. eCollection 2019 Aug 2.

[The endosymbiotic role of intestinal helminths in multiple sclerosis: Promising probiotic hypothesis.](https://www.ncbi.nlm.nih.gov/pubmed/31579670)

Karimi N, Fakhar M, Keighobadi M.

Trop Parasitol. 2019 Jul-Dec;9(2):131-132. doi: 10.4103/tp.TP\_4\_15. Epub 2019 Sep 18. No abstract available.

[Association of cigarette smoking with neuromyelitis optica-immunoglobulin G sero-positivity in neuromyelitis optica spectrum disorder.](https://www.ncbi.nlm.nih.gov/pubmed/31749929)

Eskandarieh S, Moghadasi AN, Sahraiain MA, Azimi AR, Molazadeh N.

Iran J Neurol. 2019 Jul 6;18(3):93-98.

[Correction: Epidemiology of multiple sclerosis in Iran: A systematic review and meta-analysis.](https://www.ncbi.nlm.nih.gov/pubmed/31287842)

Azami M, YektaKooshali MH, Shohani M, Khorshidi A, Mahmudi L.

PLoS One. 2019 Jul 9;14(7):e0219466. doi: 10.1371/journal.pone.0219466. eCollection 2019.

[The prevalence of multiple sclerosis continues to increase in Kuwait.](https://www.ncbi.nlm.nih.gov/pubmed/31055174)

Alroughani R, AlHamdan F, Shuaibi S, Ahmed SF, Behbehani R, Lamdhade S, Al-Hashel J.

Mult Scler Relat Disord. 2019 Jul;32:74-76. doi: 10.1016/j.msard.2019.04.033. Epub 2019 Apr 29.

[The role of nutritional factors during adolescence in multiple sclerosis onset: a population-based incident case-control study.](https://www.ncbi.nlm.nih.gov/pubmed/31362644)

Abdollahpour I, Sormani MP, Nedjat S, Mansournia MA, van der Mei I.

Nutr Neurosci. 2019 Jul 31:1-8. doi: 10.1080/1028415X.2019.1647689. [Epub ahead of print]

[The association between dietary sugar intake and neuromyelitis optica spectrum disorder: A case-control study.](https://www.ncbi.nlm.nih.gov/pubmed/30978652)

Rezaeimanesh N, Razeghi Jahromi S, Ghorbani Z, Beladi Moghadam N, Hekmatdoost A, Naser Moghadasi A, Azimi AR, Sahraian MA.

Mult Scler Relat Disord. 2019 Jun;31:112-117. doi: 10.1016/j.msard.2019.03.028. Epub 2019 Apr 4.

**Immunology and Pathology**

[Interleukin 7 receptor T244I polymorphism and the multiple sclerosis susceptibility: a meta-analysis.](https://www.ncbi.nlm.nih.gov/pubmed/32062178)

Sahami-Fard MH, Mozhdeh M, Izadpanah F, Kashani HH, Nezhadi A.

J Neuroimmunol. 2020 Apr 15;341:577166. doi: 10.1016/j.jneuroim.2020.577166. Epub 2020 Jan 22. Review.

[The roles played by TLR4 in the pathogenesis of multiple sclerosis; A systematic review article.](https://www.ncbi.nlm.nih.gov/pubmed/32032617)

Asadzadeh Manjili F, Yousefi-Ahmadipour A, Kazemi Arababadi M.

Immunol Lett. 2020 Apr;220:63-70. doi: 10.1016/j.imlet.2020.02.004. Epub 2020 Feb 4. Review.

[Potential Biomarker and Therapeutic LncRNAs in Multiple Sclerosis Through Targeting Memory B Cells.](https://www.ncbi.nlm.nih.gov/pubmed/31576494)

Ghoveud E, Teimuri S, Vatandoost J, Hosseini A, Ghaedi K, Etemadifar M, Nasr Esfahani MH, Megraw TL.

Neuromolecular Med. 2020 Mar;22(1):111-120. doi: 10.1007/s12017-019-08570-6. Epub 2019 Oct 1.

[Effects of interferon and glatiramer acetate on cytokine patterns in multiple sclerosis patients.](https://www.ncbi.nlm.nih.gov/pubmed/31731047)

Ganji A, Monfared ME, Shapoori S, Nourbakhsh P, Ghazavi A, Ghasami K, Mosayebi G.

Cytokine. 2020 Feb;126:154911. doi: 10.1016/j.cyto.2019.154911. Epub 2019 Nov 12

[Pivotal cytokines and their transcription factors are the targets of guluronic acid (G2013) for inhibiting the immunopathogenesis process of multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/32103523)

Hossein-Khannazer N, Shabani S, Farokhfar M, Azizi G, Asarzadegan F, Safarpour Lima B, Mirshafeiey A.

Drug Dev Res. 2020 Feb 26. doi: 10.1002/ddr.21645. [Epub ahead of print]

[Serum and saliva total tau protein as a marker for relapsing-remitting multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31733529)

Mirzaii-Dizgah MH, Mirzaii-Dizgah MR, Mirzaii-Dizgah I.

Med Hypotheses. 2020 Feb;135:109476. doi: 10.1016/j.mehy.2019.109476. Epub 2019 Nov 11.

[Assessment of CCL27 and IL-11 in Multiple Sclerosis Patients Treated with Interferon-β and Glatiramer Acetate.](https://www.ncbi.nlm.nih.gov/pubmed/31935737)

Ebrahimi Monfared M, Shapoori S, Mosayebi G, Khansarinejad B, Ghazavi A, Rezagholizamenjany M, Ganji A.

Neuroimmunomodulation. 2019;26(6):301-306. doi: 10.1159/000505098. Epub 2020 Jan 14.

[Cannabinoid CB2 Receptor Functional Variation (Q63R) Is Associated with Multiple Sclerosis in Iranian Subjects.](https://www.ncbi.nlm.nih.gov/pubmed/31407233)

Tahamtan A, Rezaiy S, Samadizadeh S, Moradi A, Tabarraei A, Javid N, Oladnabi M, Naeimi MH.

J Mol Neurosci. 2020 Jan;70(1):26-31. doi: 10.1007/s12031-019-01395-9. Epub 2019 Aug 13.

[Mitochondrial DNA Copy Number in Peripheral Blood as a Potential Non-invasive Biomarker for Multiple Sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31902116)

Al-Kafaji G, Bakheit HF, Alharbi MA, Farahat AA, Jailani M, Ebrahin BH, Bakhiet M.

Neuromolecular Med. 2020 Jan 4. doi: 10.1007/s12017-019-08588-w.

[Protective impacts of erythropoietin on myelinization of oligodendrocytes and schwann cells in CNS and PNS following cuprizone-induced multiple sclerosis- histology, molecular, and functional studies.](https://www.ncbi.nlm.nih.gov/pubmed/31954768)

Mirzaie J, Raoofi A, Jamalpoor Z, Nezhadi A, Golmohammadi R.

J Chem Neuroanat. 2020 Jan 16;104:101750. doi: 10.1016/j.jchemneu.2020.101750. [Epub ahead of print]

[Therapeutic plasma exchange may adjust IL-6 and TGF-β signals in relapsed MS patients peripheral blood.](https://www.ncbi.nlm.nih.gov/pubmed/31899560)

Jamshidian A, Abd-Nikfarjam B, Khademi Z, Shaygannejad V, Salehi M.

J Clin Apher. 2020 Jan 3. doi: 10.1002/jca.21755. [Epub ahead of print]

[Effects of crocin in reducing DNA damage, inflammation, and oxidative stress in multiple sclerosis patients: A double-blind, randomized, and placebo-controlled trial.](https://www.ncbi.nlm.nih.gov/pubmed/31617649)

Ghiasian M, Khamisabadi F, Kheiripour N, Karami M, Haddadi R, Ghaleiha A, Taghvaei B, Oliaie SS, Salehi M, Samadi P, Ranjbar A.

J Biochem Mol Toxicol. 2019 Dec;33(12):e22410. doi: 10.1002/jbt.22410. Epub 2019 Oct 16.

[Evaluation of plasma Osteopontin level in relapsing- remitting multiple sclerosis patients compared to healthy subjects in Isfahan Province.](https://www.ncbi.nlm.nih.gov/pubmed/31795798)

Jafarinia M, Sadeghi E, Alsahebfosoul F, Etemadifar M, Jahanbani-Ardakani H.

Int J Neurosci. 2019 Dec 3:1-6. doi: 10.1080/00207454.2019.1694925. [Epub ahead of print]

[Impact of interferon β-1b, interferon β-1a and fingolimod therapies on serum interleukins-22, 32α and 34 concentrations in patients with relapsing-remitting multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31521828)

Abdel-Dayem MA, Shaker ME, Gameil NM.

J Neuroimmunol. 2019 Dec 15;337:577062. doi: 10.1016/j.jneuroim.2019.577062. Epub 2019 Sep 6.

[IL-21 and IL-21-producing T cells are involved in multiple sclerosis severity and progression.](https://www.ncbi.nlm.nih.gov/pubmed/31545959)

Gharibi T, Hosseini A, Marofi F, Oraei M, Jahandideh S, Abdollahpour-Alitappeh M, Hashemi V, Motallebnezhad M, Babaloo Z, Baradaran B.

Immunol Lett. 2019 Dec;216:12-20. doi: 10.1016/j.imlet.2019.09.003. Epub 2019 Sep 20.

[Metformin accelerates myelin recovery and ameliorates behavioral deficits in the animal model of multiple sclerosis via adjustment of AMPK/Nrf2/mTOR signaling and maintenance of endogenous oligodendrogenesis during brain self-repairing period.](https://www.ncbi.nlm.nih.gov/pubmed/32048246)

Sanadgol N, Barati M, Houshmand F, Hassani S, Clarner T, Shahlaei M, Golab F.

Pharmacol Rep. 2019 Dec 18. doi: 10.1007/s43440-019-00019-8. [Epub ahead of print]

[Metformin-induced AMPK activation stimulates remyelination through induction of neurotrophic factors, downregulation of NogoA and recruitment of Olig2+ precursor cells in the cuprizone murine model of multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31620963)

Houshmand F, Barati M, Golab F, Ramezani-Sefidar S, Tanbakooie S, Tabatabaei M, Amiri M, Sanadgol N.

Daru. 2019 Dec;27(2):583-592. doi: 10.1007/s40199-019-00286-z. Epub 2019 Oct 16.

[Serum levels of IL-6 and IL-17 in multiple sclerosis, neuromyelitis optica patients and healthy subjects.](https://www.ncbi.nlm.nih.gov/pubmed/31993101)

Ashtari F, Madanian R, Shaygannejad V, Zarkesh SH, Ghadimi K.

Int J Physiol Pathophysiol Pharmacol. 2019 Dec 15;11(6):267-273. eCollection 2019.

[The role of immune regulatory molecules in multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31520791)

Afshar B, Khalifehzadeh-Esfahani Z, Seyfizadeh N, Rezaei Danbaran G, Hemmatzadeh M, Mohammadi H.

J Neuroimmunol. 2019 Dec 15;337:577061. doi: 10.1016/j.jneuroim.2019.577061. Epub 2019 Sep 5. Review.

[Interleukin 18 Polymorphisms and its serum level in Patients with Multiple Sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31736573)

Jahanbani-Ardakani H, Alsahebfosoul F, Etemadifar M, Abtahi SH.

Ann Indian Acad Neurol. 2019 Oct-Dec;22(4):474-476. doi: 10.4103/aian.AIAN\_515\_18. Epub 2019 Oct 25.

[Immunoglobulin G index as a biomarker of relapse response to corticosteroids during early stages of multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31715505)

Talaat F, Ramadan I, Hamdy E, Sayed A, Elfatatry AM.

Mult Scler Relat Disord. 2019 Nov 6;38:101495. doi: 10.1016/j.msard.2019.101495.

[Glutamate and Nitric Oxide as biomarkers for disease activity in patients with multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31816505)

Abdel Naseer M, Rabah AM, Rashed LA, Hassan A, Fouad AM.

Mult Scler Relat Disord. 2019 Nov 25;38:101873. doi: 10.1016/j.msard.2019.101873.

[Evaluation of glucose-6-phosphate dehydrogenase serum level in patients with multiple sclerosis and neuromyelitis optica.](https://www.ncbi.nlm.nih.gov/pubmed/32117550)

Chitsaz N, Dehghani L, Safi A, Esmalian-Afyouni N, Shaygannejad V, Rezvani M, Sohrabi K, Moridi K, Moayednia M.

Iran J Neurol. 2019 Oct 7;18(4):150-153.

[Evaluation of apamin effects on myelination process in C57BL/6 mice model of multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31798659)

Mohammadi-Rad M, Ghasemi N, Aliomrani M.

Res Pharm Sci. 2019 Oct 4;14(5):424-431. doi: 10.4103/1735-5362.268203. eCollection 2019 Oct.

[Gut microbiota depletion from early adolescence alters adult immunological and neurobehavioral responses in a mouse model of multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31247271)

Zeraati M, Enayati M, Kafami L, Shahidi SH, Salari AA.

Neuropharmacology. 2019 Oct;157:107685. doi: 10.1016/j.neuropharm.2019.107685. Epub 2019 Jun 25.

 [When an octopus has MS: Application of neurophysiology and immunology of octopuses for multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31443774)

Naser Moghadasi A.

Med Hypotheses. 2019 Oct;131:109297. doi: 10.1016/j.mehy.2019.109297. Epub 2019 Jul 1.

[Evaluation of treatment of experimentally induced canine model of multiple sclerosis using laser activated non-expanded adipose derived stem cells.](https://www.ncbi.nlm.nih.gov/pubmed/31152923)

Abdallah AN, Shamaa AA, El-Tookhy OS.

Res Vet Sci. 2019 Aug;125:71-81. doi: 10.1016/j.rvsc.2019.05.016. Epub 2019 May 22.

[Elevated serum level of IL-4 in neuromyelitis optica and multiple sclerosis patients.](https://www.ncbi.nlm.nih.gov/pubmed/31422745)

Tahani S, Dehghani L, Jahanbani-Ardakani H, Shaygannejad V, Fazli A, Hamidavi A, Eskandari N.

J Immunoassay Immunochem. 2019;40(5):555-563. doi: 10.1080/15321819.2019.1655649. Epub 2019 Aug 19.

[Micro-RNA-96 and interleukin-10 are independent biomarkers for multiple sclerosis activity.](https://www.ncbi.nlm.nih.gov/pubmed/31238191)

Sedeeq MS, El-Nahrery EMA, Shalaby N, Hussein M, Shehata H, El Aal RA, Abdel Ghaffar NF, Mohamed MM.

J Neurol Sci. 2019 Aug 15;403:92-96. doi: 10.1016/j.jns.2019.06.022. Epub 2019 Jun 19.

[Plasma levels of CTRP-3, CTRP-9 and apelin in women with multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31129285)

Rasooli Tehrani A, Gholipour S, Sharifi R, Yadegari S, Abbasi-Kolli M, Masoudian N.

J Neuroimmunol. 2019 Aug 15;333:576968. doi: 10.1016/j.jneuroim.2019.576968. Epub 2019 May 16.

[Elevated CSF concentration of CCL3 and CCL4 in relapsing remitting multiple sclerosis patients.](https://www.ncbi.nlm.nih.gov/pubmed/31268406)

Soleimani M, Soleymani A, Seyyedirad N.

J Immunoassay Immunochem. 2019;40(4):378-385. doi: 10.1080/15321819.2019.1613242. Epub 2019 Jul 3.

[Evaluation of IL-17 Serum Level, Brain Inflammation and Demyelination in Experimental Autoimmune Encephalomyelitis C57BL/6 Mice Model with Different Doses of Myelin Oligodendrocyte Glycoprotein.](https://www.ncbi.nlm.nih.gov/pubmed/31522437)

Ghorbani MM, Farazmandfar T, Nasirikenari M, Abediankenari S, Meamarian A, Shahbazi M.

Iran J Allergy Asthma Immunol. 2019 Jun 8;18(3):300-309. doi: 10.18502/ijaai.v18i3.1123.

[Oligoprotective effect of metformin through the AMPK-dependent on restoration of mitochondrial hemostasis in the cuprizone-induced multiple sclerosis model.](https://www.ncbi.nlm.nih.gov/pubmed/31016544)

Largani SHH, Borhani-Haghighi M, Pasbakhsh P, Mahabadi VP, Nekoonam S, Shiri E, Kashani IR, Zendehdel A.

J Mol Histol. 2019 Jun;50(3):263-271. doi: 10.1007/s10735-019-09824-0. Epub 2019 Apr 23.

[Serum level measurement of progranulin in relapsing-remitting multiple sclerosis and neuromyelitis optica patients.](https://www.ncbi.nlm.nih.gov/pubmed/31316865)

Azadani NN, Norouzi F, Hajizadeh M, Parsa S, Khalighinejad F.

Am J Clin Exp Immunol. 2019 Jun 15;8(3):16-20. eCollection 2019.

[The Toll-like Receptor 2 (TLR2)-related Immunopathological Responses in the Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.](https://www.ncbi.nlm.nih.gov/pubmed/31522431)

Jafarzadeh A, Nemati M, Khorramdelazad H, Mirshafiey A.

Iran J Allergy Asthma Immunol. 2019 Jun 8;18(3):230-250. doi: 10.18502/ijaai.v18i3.1117. Review.

[Angiopoietin-like proteins in multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/30784773)

Al-Temaimi R, Cherian P, Abu-Farha M, Alroughani R.

J Neuroimmunol. 2019 May 15;330:31-34. doi: 10.1016/j.jneuroim.2019.02.006. Epub 2019 Feb 15.

**Genetics**

[Comparison of The Expression of miR-326 between Interferon beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31606972)

Fattahi M, Eskandari N, Sotoodehnejadnematalahi F, Shaygannejad V, Kazemi M.

Cell J. 2020 Apr;22(1):92-95. doi: 10.22074/cellj.2020.6486. Epub 2019 Sep 8.

[Exercise modulates the levels of growth inhibitor genes before and after multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/32028123)

Shahidi SH, Kordi MR, Rajabi H, Malm C, Shah F, Quchan ASK.

J Neuroimmunol. 2020 Apr 15;341:577172. doi: 10.1016/j.jneuroim.2020.577172. Epub 2020 Jan 30.

[Male microchimerism in peripheral blood from women with multiple sclerosis in Isfahan Province.](https://www.ncbi.nlm.nih.gov/pubmed/31833227)

Jafarinia M, Amoon M, Javid A, Vakili S, Sadeghi E, Azadi D, Alsahebfosoul F.

Int J Immunogenet. 2020 Apr;47(2):175-179. doi: 10.1111/iji.12465. Epub 2019 Dec 12.

[Association of Interleukin-1 and Inteleukin-1 Receptor Antagonist Gene Polymorphisms with Multiple Sclerosis in Azeri Population of Iran.](https://www.ncbi.nlm.nih.gov/pubmed/32148206)

Asgharzadeh M, Jigheh ZA, Kafil HS, Farhoudi M, Oskouei DS, Khaki-Khatibi F, Fadaee M, Vegari A, Asgharzadeh V, Najafi-Ghalelou N, Poor BM, Rashedi J.

Endocr Metab Immune Disord Drug Targets. 2020 Mar 9.

[Differential expression of STAT3 gene and its regulatory long non-coding RNAs, namely lnc-DC and THRIL, in two eastern Iranian ethnicities with multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31713760)

Pahlevan Kakhki M, Rakhshi N, Emami Aleagha MS, Abdari M, Alikhah A, Safarian G, Behmanesh M, Nikravesh A.

Neurol Sci. 2020 Mar;41(3):561-568. doi: 10.1007/s10072-019-04092-y. Epub 2019 Nov 12.

[The Putative Association of TOB1-AS1 Long Non-coding RNA with Immune Tolerance: A Study on Multiple Sclerosis Patients.](https://www.ncbi.nlm.nih.gov/pubmed/31482275)

Dehghanzad R, Pahlevan Kakhki M, Alikhah A, Sahraian MA, Behmanesh M.

Neuromolecular Med. 2020 Mar;22(1):100-110. doi: 10.1007/s12017-019-08567-1. Epub 2019 Sep 3.

[Association of Multiple Sclerosis Phenotypes with Single Nucleotide Polymorphisms of *IL7R, LAG3*, and *CD40* Genes in a Jordanian Population: A Genotype-Phenotype Study.](https://www.ncbi.nlm.nih.gov/pubmed/32111053)

Al-Eitan L, Qudah MA, Qawasmeh MA.

Biomolecules. 2020 Feb 26;10(3). pii: E356. doi: 10.3390/biom10030356.

[Associations Between Genomic Variants in lncRNA-TRPM2-AS and lncRNA-HNF1A-AS1 Genes and Risk of Multiple Sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/32100228)

Bahrami T, Taheri M, Omrani MD, Karimipoor M.

J Mol Neurosci. 2020 Feb 26. doi: 10.1007/s12031-020-01504-z. [Epub ahead of print]

[Epigenetic aspects of multiple sclerosis and future therapeutic options.](https://www.ncbi.nlm.nih.gov/pubmed/32075477)

Jamebozorgi K, Rostami D, Pormasoumi H, Taghizadeh E, Barreto GE, Sahebkar A.

Int J Neurosci. 2020 Feb 25:1-9. doi: 10.1080/00207454.2020.1732974. [Epub ahead of print]

[Modulation of Th17 Proliferation and IL-17A Gene Expression by Acetylated Form of Apigenin in Patients with Multiple Sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/32100582)

Rahmati M, Ghannadian SM, Kasiri N, Ahmadi L, Motedayyen H, Shaygannejad V, Pourazar A, Alsahebfosoul F, Ganjalikhani Hakemi M, Eskandari N.

Immunol Invest. 2020 Feb 26:1-14. doi: 10.1080/08820139.2020.1726381. [Epub ahead of print]

[The rs4759314 SNP within Hotair lncRNA is associated with risk of multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/32058948)

Taheri M, Noroozi R, Sadeghpour S, Omrani MD, Ghafouri-Fard S.

Mult Scler Relat Disord. 2020 Feb 6;40:101986. doi: 10.1016/j.msard.2020.101986. [Epub ahead of print]

[Vitamin D receptor genetic polymorphisms and the risk of multiple sclerosis: A systematic review and meta-analysis.](https://www.ncbi.nlm.nih.gov/pubmed/32097613)

Mohammadi A, Azarnezhad A, Khanbabaei H, Izadpanah E, Abdollahzadeh R, Barreto GE, Sahebkar A.

Steroids. 2020 Feb 22;158:108615. doi: 10.1016/j.steroids.2020.108615. [Epub ahead of print] Review.

[Identification of common key genes and pathways between type 1 diabetes and multiple sclerosis using transcriptome and interactome analysis.](https://www.ncbi.nlm.nih.gov/pubmed/31912409)

Safari-Alighiarloo N, Taghizadeh M, Mohammad Tabatabaei S, Namaki S, Rezaei-Tavirani M.

Endocrine. 2020 Jan 7. doi: 10.1007/s12020-019-02181-8. [Epub ahead of print]

[Genetic and Molecular Biology of Multiple Sclerosis Among Iranian Patients: An Overview.](https://www.ncbi.nlm.nih.gov/pubmed/31482432)

Moghbeli M.

Cell Mol Neurobiol. 2020 Jan;40(1):65-85. doi: 10.1007/s10571-019-00731-2. Epub 2019 Sep 3. Review.

[Multiple sclerosis and human leukocyte antigen genotypes: Focus on the Middle East and North Africa region.](https://www.ncbi.nlm.nih.gov/pubmed/31976083)

Maghbooli Z, Sahraian MA, Naser Moghadasi A.

Mult Scler J Exp Transl Clin. 2020 Jan 9;6(1):2055217319881775. doi: 10.1177/2055217319881775. eCollection 2020 Jan-Mar.

[Upregulation of VEGF-A and correlation between VEGF-A and FLT-1 expressions in Iranian multiple sclerosis patients.](https://www.ncbi.nlm.nih.gov/pubmed/31925615)

Azimi G, Ranjbaran F, Arsang-Jang S, Ghafouri-Fard S, Mazdeh M, Sayad A, Taheri M.

Neurol Sci. 2020 Jan 11. doi: 10.1007/s10072-019-04234-2. [Epub ahead of print]

[Correlation between LincR-Gng2-5'and LincR-Epas1-3'as with the severity of multiple sclerosis in Egyptian patients.](https://www.ncbi.nlm.nih.gov/pubmed/31790618)

Shaker OG, Golam RM, Ayoub S, Daker LI, Elguaad MKA, Said ES, Khalil MAF.

Int J Neurosci. 2019 Dec 2:1-7. doi: 10.1080/00207454.2019.1695610.

[Effects of guluronic acid (G2013) on gene expression of TLR2, TLR4, MyD88, TNF-α and CD52 in multiple sclerosis under in vitro conditions.](https://www.ncbi.nlm.nih.gov/pubmed/31594427)

Noorbakhsh SM, Razavi A, Moghadam NB, Saadat P, Hoseini M, Aghazadeh Z, Mobini M, Oraei M, Mirshafiey A.

Immunopharmacol Immunotoxicol. 2019 Dec;41(6):586-590. doi: 10.1080/08923973.2019.1672179. Epub 2019 Oct 8.

[Four novel mutations in the mitochondrial *ND4* gene of complex I in patients with multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31798871)

Alharbi MA, Al-Kafaji G, Khalaf NB, Messaoudi SA, Taha S, Daif A, Bakhiet M.

Biomed Rep. 2019 Dec;11(6):257-268. doi: 10.3892/br.2019.1250.

[LncRNAs associated with multiple sclerosis expressed in the Th1 cell lineage.](https://www.ncbi.nlm.nih.gov/pubmed/31066039)

Hosseini A, Teimuri S, Ehsani M, Rasa SMM, Etemadifar M, Nasr Esfahani MH, Megraw TL, Ghaedi K.

J Cell Physiol. 2019 Dec;234(12):22153-22162. doi: 10.1002/jcp.28779. Epub 2019 May 8.

[Nicotinamide nucleotide transhydrogenase expression analysis in multiple sclerosis patients.](https://www.ncbi.nlm.nih.gov/pubmed/31474168)

Eftekharian MM, Taheri M, Arsang-Jang S, Komaki A, Ghafouri-Fard S.

Int J Neurosci. 2019 Dec;129(12):1256-1260. doi: 10.1080/00207454.2019.1660655. Epub 2019 Sep 2.

[The evaluation of VEGF and HIF-1α gene polymorphisms and multiple sclerosis susceptibility.](https://www.ncbi.nlm.nih.gov/pubmed/31652374)

Saravani M, Rokni M, Mehrbani M, Amirkhosravi A, Faramarz S, Fatemi I, Esmaeili Tarzi M, Nematollahi MH.

J Gene Med. 2019 Dec;21(12):e3132. doi: 10.1002/jgm.3132. Epub 2019 Dec 9.

[The FTO gene polymorphism rs9939609 is associated with obesity and disability in multiple sclerosis patients.](https://www.ncbi.nlm.nih.gov/pubmed/31836807)

Al-Serri A, Alroughani R, Al-Temaimi RA.

Sci Rep. 2019 Dec 13;9(1):19071. doi: 10.1038/s41598-019-55742-2.

[Altered expression patterns of complement factor H and miR-146a genes in acute-chronic phases in experimental autoimmune encephalomyelitis mouse.](https://www.ncbi.nlm.nih.gov/pubmed/30972735)

Gharibi S, Moghimi B, Haghmorad D, Mahmoudi MB, Shahvazian E, Yadegari M, Yazd EF, Tahoori MT.

J Cell Physiol. 2019 Nov;234(11):19842-19851. doi: 10.1002/jcp.28583. Epub 2019 Apr 10.

[Association between interleukin-4 and interleukin-10 single nucleotide polymorphisms and multiple sclerosis among Iraqi patients.](https://www.ncbi.nlm.nih.gov/pubmed/31264107)

Al-Naseri MA, Salman ED, Ad'hiah AH.

Neurol Sci. 2019 Nov;40(11):2383-2389. doi: 10.1007/s10072-019-04000-4. Epub 2019 Jul 1.

[Leptin rs7799039 polymorphism is associated with multiple sclerosis risk in Kuwait.](https://www.ncbi.nlm.nih.gov/pubmed/31563075)

Dashti M, Alroughani R, Jacob S, Al-Temaimi R.

Mult Scler Relat Disord. 2019 Nov;36:101409. doi: 10.1016/j.msard.2019.101409. Epub 2019 Sep 24.

[Long noncoding RNAs APOA1-AS, IFNG-AS1, RMRP and their related biomolecules in Egyptian patients with relapsing-remitting multiple sclerosis: Relation to disease activity and patient disability.](https://www.ncbi.nlm.nih.gov/pubmed/32071782)

Ghaiad HR, Elmazny AN, Nooh MM, El-Sawalhi MM, Shaheen AA.

J Adv Res. 2019 Nov 4;21:141-150. doi: 10.1016/j.jare.2019.10.012. eCollection 2020 Jan.

[Role of *NR3C1* and *GAS5* genes polymorphisms in multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31724909)

Moradi M, Gharesouran J, Ghafouri-Fard S, Noroozi R, Talebian S, Taheri M, Rezazadeh M.

Int J Neurosci. 2019 Nov 26:1-6. doi: 10.1080/00207454.2019.1694019. [Epub ahead of print]

[A single nucleotide polymorphism within Ninjurin 2 is associated with risk of multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31292852)

Noroozi R, Azari I, Taheri M, Omrani MD, Ghafouri-Fard S.

Metab Brain Dis. 2019 Oct;34(5):1415-1419. doi: 10.1007/s11011-019-00460-x. Epub 2019 Jul 10.

[Circulating mesenchymal stem cells, stromal derived factor (SDF)-1 and IP-10 levels increased in clinically active multiple sclerosis patients but not in clinically stable patients treated with beta interferon.](https://www.ncbi.nlm.nih.gov/pubmed/31421626)

Emamnejad R, Sahraian M, Shakiba Y, Salehi Z, Masoomi A, Imani D, Najafi F, Laribi B, Shirzad H, Izad M.

Mult Scler Relat Disord. 2019 Oct;35:233-238. doi: 10.1016/j.msard.2019.08.013. Epub 2019 Aug 12.

[Down-regulation of ERMN expression in relapsing remitting multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31123898)

Salek Esfahani B, Gharesouran J, Ghafouri-Fard S, Talebian S, Arsang-Jang S, Omrani MD, Taheri M, Rezazadeh M.

Metab Brain Dis. 2019 Oct;34(5):1261-1266. doi: 10.1007/s11011-019-00429-w. Epub 2019 May 23.

[Identification of Multiple Sclerosis key genetic factors through multi-staged data mining.](https://www.ncbi.nlm.nih.gov/pubmed/31874362)

Navaderi M, Rajaei S, Rahimirad S, Jafari Harandi A, Ghaleh Z, Falahati K, Behgar Z, Sedigh AM, Sanati MH.

Mult Scler Relat Disord. 2019 Oct 22;39:101446. doi: 10.1016/j.msard.2019.101446. [Epub ahead of print] No abstract available.

[MicroRNA-29b variants and MxA expression change during interferon beta therapy in patients with relapsing-remitting multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31421628)

Fattahi M, Rezaei N, Nematalahi FS, Shaygannejad V, Fouladi S, Karimi L, Fathi F, Dehghani L, Mirmosayyeb O, Eskandari N.

Mult Scler Relat Disord. 2019 Oct;35:241-245. doi: 10.1016/j.msard.2019.07.034. Epub 2019 Jul 31.

[The efficacy of interferon-beta therapy in multiple sclerosis patients: investigation of the RORA gene as a predictive biomarker.](https://www.ncbi.nlm.nih.gov/pubmed/31649263)

Ayatollahi SA, Ghafouri-Fard S, Taheri M, Noroozi R.

Pharmacogenomics J. 2019 Oct 24. doi: 10.1038/s41397-019-0114-0. [Epub ahead of print]

[Association Study between Functional Polymorphisms of *MMP9* Gene Promoter and Multiple Sclerosis Susceptibility in an Iranian Population.](https://www.ncbi.nlm.nih.gov/pubmed/31700826)

Sabbagh S, Nadeali Z, Dehghani L, Shaygannejad V, Rezvani M, Saboori M, Ganji H, Tahani S, Dehghani F, Hosseinzadeh S, Marzbani E, Shafiei P.

Iran J Public Health. 2019 Sep;48(9):1697-1703

[Development of α4 integrin DNA aptamer as a potential therapeutic tool for multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31111537)

Kouhpayeh S, Hejazi Z, Boshtam M, Mirian M, Rahimmanesh I, Darzi L, Rezaei A, Shariati L, Khanahmad H.

J Cell Biochem. 2019 Sep;120(9):16264-16272. doi: 10.1002/jcb.28907. Epub 2019 May 20.

[Genetic polymorphisms and epigenetic regulation of survivin encoding gene, BIRC5, in multiple sclerosis patients.](https://www.ncbi.nlm.nih.gov/pubmed/31438837)

Rahban D, Mohammadi F, Alidadi M, Ghantabpour T, Kheyli PAG, Ahmadi M.

BMC Immunol. 2019 Aug 22;20(1):30. doi: 10.1186/s12865-019-0312-1.

[Hepatocellular carcinoma up-regulated long non-coding RNA: a putative marker in multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31049796)

Sayad A, Taheri M, Arsang-Jang S, Glassy MC, Ghafouri-Fard S.

Metab Brain Dis. 2019 Aug;34(4):1201-1205. doi: 10.1007/s11011-019-00418-z. Epub 2019 May 2.

[Evaluation of The Expression Levels of Three Long Non-Coding RNAs in Multiple Sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31721530)

Moradi A, Rahimi Naiini M, Yazdanpanahi N, Tabatabaeian H, Nabatchian F, Baghi M, Azadeh M, Ghaedi K.

Cell J. 2020 Jul;22(2):165-170. doi: 10.22074/cellj.2020.6555. Epub 2019 Oct 14.

[Matrix metalloproteases 9 rs3918242 gene polymorphism and serum vit D in MS Egyptian patients.](https://www.ncbi.nlm.nih.gov/pubmed/31082619)

Ibrahim I, Wassefy ME, Metwally SS, Elmenshawi I.

Mult Scler Relat Disord. 2019 Jul;32:103-106. doi: 10.1016/j.msard.2019.04.029. Epub 2019 May 3.

[Neuronal methylome reveals CREB-associated neuro-axonal impairment in multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31146783)

Kular L, Needhamsen M, Adzemovic MZ, Kramarova T, Gomez-Cabrero D, Ewing E, Piket E, Tegnér J, Beck S, Piehl F, Brundin L, Jagodic M.

Clin Epigenetics. 2019 May 30;11(1):86. doi: 10.1186/s13148-019-0678-1.

**Clinical Aspects**

[Impact of depression and fatigue on relapsing remitting multiple sclerosis in Kingdom of Saudi Arabia.](https://www.ncbi.nlm.nih.gov/pubmed/32114602)

Alshamrani FJ, Almuaigel MF, Alkhamis FA, Alsulaiman AA, AlMohish NM, Albuhassah AF, AlZahrani AS, Mahmoud Zaher AA.

Saudi Med J. 2020 Mar;41(3):290-295. doi: 10.15537/smj.2020.3.24910.

[A simple mathematical model for relapsing-remitting multiple sclerosis (RRMS).](https://www.ncbi.nlm.nih.gov/pubmed/31733531)

Elettreby MF, Ahmed E.

Med Hypotheses. 2020 Feb;135:109478. doi: 10.1016/j.mehy.2019.109478. Epub 2019 Nov 11.

[Clinical findings and outcomes of uveitis associated with multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/32019337)

AlBloushi AF, Dheyab AM, Al-Swaina NF, Al-Obailan M, Daif AK, Abu El-Asrar AM.

Eur J Ophthalmol. 2020 Feb 4:1120672120904667. doi: 10.1177/1120672120904667. [Epub ahead of print]

[Cognitive functions in Egyptian neuromyelitis optica spectrum disorder.](https://www.ncbi.nlm.nih.gov/pubmed/31790906)

Salama S, Marouf H, Reda MI, Mansour AR, ELKholy O, Levy M.

Clin Neurol Neurosurg. 2020 Feb;189:105621

[Restless legs syndrome among multiple sclerosis patients in Lebanon.](https://www.ncbi.nlm.nih.gov/pubmed/32113183)

Makhoul J, Ghaoui N, Sleilaty G, Koussa S, Abbas S, Azar C, El Helou J.

Mult Scler Relat Disord. 2020 Feb 11;41:101997. doi: 10.1016/j.msard.2020.101997. [Epub ahead of print]

[Sexual dysfunction in women with multiple sclerosis: prevalence and impact on quality of life.](https://www.ncbi.nlm.nih.gov/pubmed/32085755)

Nazari F, Shaygannejad V, Mohammadi Sichani M, Mansourian M, Hajhashemi V.

BMC Urol. 2020 Feb 21;20(1):15. doi: 10.1186/s12894-020-0581-2.

[The effect of cortical versus sacral repetitive magnetic stimulation on lower urinary tract dysfunction in patients with multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31828602)

El-Habashy H, Nada MM, Maher EA, Shamloul R, Maged M, Abdelazim MS.

Acta Neurol Belg. 2020 Feb;120(1):141-147. doi: 10.1007/s13760-019-01257-6. Epub 2019 Dec 11.

[Aggressive course of cognitive impairment in multiple sclerosis: A new term for the management of patients.](https://www.ncbi.nlm.nih.gov/pubmed/31495660)

Naser Moghadasi A, Sahraian MA.

J Clin Neurosci. 2020 Jan;71:308-310. doi: 10.1016/j.jocn.2019.08.104. Epub 2019 Sep 5.

[Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations.](https://www.ncbi.nlm.nih.gov/pubmed/32128285)

Canibaño B, Deleu D, Mesraoua B, Melikyan G, Ibrahim F, Hanssens Y.

J Drug Assess. 2020 Jan 23;9(1):20-36. doi: 10.1080/21556660.2020.1721507. eCollection 2020.

[Pregnancy and Motherhood Concerns Surrounding Women with Multiple Sclerosis: A Qualitative Content Analysis.](https://www.ncbi.nlm.nih.gov/pubmed/32039275)

Ghafoori F, Dehghan-Nayeri N, Khakbazan Z, Hedayatnejad M, Nabavi SM.

Int J Community Based Nurs Midwifery. 2020 Jan;8(1):2-11. doi: 10.30476/IJCBNM.2019.73900.0.

[The effect of foot reflexology on constipation and quality of life in patients with multiple sclerosis. A randomized controlled trial.](https://www.ncbi.nlm.nih.gov/pubmed/31987235)

Sajadi M, Davodabady F, Naseri-Salahshour V, Harorani M, Ebrahimi-Monfared M.

Complement Ther Med. 2020 Jan;48:102270. doi: 10.1016/j.ctim.2019.102270. Epub 2019 Nov 29. Erratum in:

[The prevalence of lower urinary tract symptoms based on individual and clinical parameters in patients with multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31952513)

Nazari F, Shaygannejad V, Mohammadi Sichani M, Mansourian M, Hajhashemi V.

BMC Neurol. 2020 Jan 17;20(1):24. doi: 10.1186/s12883-019-1582-1.

[Compared to an active control condition, in persons with multiple sclerosis two different types of exercise training improved sleep and depression, but not fatigue, paresthesia, and intolerance of uncertainty.](https://www.ncbi.nlm.nih.gov/pubmed/31521917)

Sadeghi Bahmani D, Razazian N, Farnia V, Alikhani M, Tatari F, Brand S.

Mult Scler Relat Disord. 2019 Nov;36:101356. doi: 10.1016/j.msard.2019.07.032. Epub 2019 Jul 29.

[Estimating the prevalence of cognition and mental health among multiple sclerosis patients: A population-based cross-sectional study.](https://www.ncbi.nlm.nih.gov/pubmed/31557677)

Khader HA, Emran B, Sulaimi MA, Abdulhadi DA, Obaidli KA, Deai AA, Albatineh AN.

Mult Scler Relat Disord. 2019 Nov;36:101391. doi: 10.1016/j.msard.2019.101391. Epub 2019 Sep 10.

[The correlation between dyslipidemia and cognitive impairment in multiple sclerosis patients.](https://www.ncbi.nlm.nih.gov/pubmed/31586799)

Noori H, Gheini MR, Rezaeimanesh N, Saeedi R, Rezaei Aliabadi H, Sahraian MA, Naser Moghadasi A.

Mult Scler Relat Disord. 2019 Nov;36:101415. doi: 10.1016/j.msard.2019.101415. Epub 2019 Sep 26.

[Pattern of Intermediate Uveitis in an Egyptian Cohort.](https://www.ncbi.nlm.nih.gov/pubmed/31642742)

Abd El Latif E, Abdelhalim AS, Montasser AS, Said MH, Shikhoun Ahmed M, Abdel Kader Fouly Galal M, Ibrahim W, Samy Abd Elaziz M, Fathi Abuelkheir A, Elbarbary H, Elsayed AMA, Lotfy A, Elmorsy OA, Gab-Alla AA, Hatata RM, Abousamra AAH, Farouk MM, Elbakary MA, Awara AM, Amer I, Elzawahry WMAE, Kandil HW, Barrada OA, Bakr Elessawy K, Zayed MA, El Hennawi H, Tawfik MA.

Ocul Immunol Inflamm. 2019 Oct 23:1-8. doi: 10.1080/09273948.2019.1668429. [Epub ahead of print]

[Risk of relapses during pregnancy among multiple sclerosis patients.](https://www.ncbi.nlm.nih.gov/pubmed/31202959)

Alroughani R, Akhtar S, Zeineddine M, El Kouzi Y, El Ayoubi NK, Ahmed SF, Behbehani R, Khoury SJ, Al-Hashel JY, Yamout BI.

Mult Scler Relat Disord. 2019 Sep;34:9-13.

[Cognitive and physical disability in Egyptian patients with multiple sclerosis: genetic and optical coherence tomography study.](https://www.ncbi.nlm.nih.gov/pubmed/31025605)

Abdel Naseer M, Fathi S, Roshdy NK, Labib DM, Khalil DH, Ibrahim W, Magdy R.

Neurol Res. 2019 Jul;41(7):644-651. doi: 10.1080/01616412.2019.1609203. Epub 2019 Apr 26.

[Effects of enhanced environment and induced depression on cuprizone mouse model of demyelination.](https://www.ncbi.nlm.nih.gov/pubmed/31281443)

Mohamed A, Al-Kafaji G, Almahroos A, Almosawi Z, Alalwan H, Abdulla R, Alammadi F, Almubarak A, Al-Mahrezi A, Kamal A.

Exp Ther Med. 2019 Jul;18(1):566-572. doi: 10.3892/etm.2019.7654.

[Management of seizures in patients with multiple sclerosis; an Iranian consensus.](https://www.ncbi.nlm.nih.gov/pubmed/31151870)

Asadi-Pooya AA, Sahraian MA, Sina F, Baghbanian SM, Habibabadi JM, Shaygannejad V, Asadollahi M, Karvigh SA, Moghadasi AN, Nikseresht A, Motamedi M.

Epilepsy Behav. 2019 Jul;96:244-248. doi: 10.1016/j.yebeh.2019.04.032. Review.

[Paroxysmal dystonia as an initial presentation of multiple sclerosis posing a diagnostic challenge.](https://www.ncbi.nlm.nih.gov/pubmed/31380825)

Al Dehailan AS.

Neurosciences (Riyadh). 2019 Jul;24(3):236-239. doi: 10.17712/nsj.2018.3.20190025.

[The relationship between cognitive function and body mass index in multiple sclerosis patients.](https://www.ncbi.nlm.nih.gov/pubmed/31030017)

Owji M, Ashraf-Ganjouei A, Sahraian MA, Bidadian M, Ghadiri F, Naser Moghadasi A.

Mult Scler Relat Disord. 2019 Jul;32:37-40. doi: 10.1016/j.msard.2019.04.024. Epub 2019 Apr 21.

[In Patients With Multiple Sclerosis, Both Objective and Subjective Sleep, Depression, Fatigue, and Paresthesia Improved After 3 Weeks of Regular Exercise.](https://www.ncbi.nlm.nih.gov/pubmed/31130879)

Sadeghi Bahmani D, Kesselring J, Papadimitriou M, Bansi J, Pühse U, Gerber M, Shaygannejad V, Holsboer-Trachsler E, Brand S.

Front Psychiatry. 2019 May 3;10:265. doi: 10.3389/fpsyt.2019.00265. eCollection 2019

**Neuroimaging**

[Optimization of spectral domain optical coherence tomography and visual evoked potentials to identify unilateral optic neuritis.](https://www.ncbi.nlm.nih.gov/pubmed/32092503)

Behbehani R, Ali A, Al-Omairah H, Rousseff RT.

Mult Scler Relat Disord. 2020 Feb 7;41:101988. doi: 10.1016/j.msard.2020.101988. [Epub ahead of print]

["No evidence of disease activity": Is it an aspirational therapeutic goal in multiple sclerosis?](https://www.ncbi.nlm.nih.gov/pubmed/31951861)

Mayssam EN, Eid C, Khoury SJ, Hannoun S.

Mult Scler Relat Disord. 2020 Jan 9;40:101935. doi: 10.1016/j.msard.2020.101935. [Epub ahead of print] Review.

[Retinal Nerve Fiber Layer Thickness and Total Macular Volume in Multiple Sclerosis Subtypes and Their Relationship with Severity of Disease, a Cross-Sectional Study.](https://www.ncbi.nlm.nih.gov/pubmed/32021529)

Eslami F, Ghiasian M, Khanlarzade E, Moradi E.

Eye Brain. 2020 Jan 17;12:15-23. doi: 10.2147/EB.S229814. eCollection 2020.

[Granger causality analysis in combination with directed network measures for classification of MS patients and healthy controls using task-related fMRI.](https://www.ncbi.nlm.nih.gov/pubmed/31698238)

Azarmi F, Miri Ashtiani SN, Shalbaf A, Behnam H, Daliri MR.

Comput Biol Med. 2019 Dec;115:103495. doi: 10.1016/j.compbiomed.2019.103495. Epub 2019 Oct 13.

[Multiple Sclerosis Lesions Segmentation in Magnetic Resonance Imaging using Ensemble Support Vector Machine (ESVM).](https://www.ncbi.nlm.nih.gov/pubmed/32039101)

HosseiniPanah S, Zamani A, Emadi F, HamtaeiPour F.

J Biomed Phys Eng. 2019 Dec 1;9(6):699-710. doi: 10.31661/jbpe.v0i0.986. eCollection 2019 Dec.

[Magnetic resonance imaging markers of disability in Egyptian multiple sclerosis patients.](https://www.ncbi.nlm.nih.gov/pubmed/31568984)

Abdelhafeez MA, Zamzam DA, Foad MM, Swelam MS, Abdelnasser A, Aref HA, Ibrahim YA, Khater NH, Darwish EA, Zakaria MF.

Mult Scler Relat Disord. 2019 Nov;36:101417. doi: 10.1016/j.msard.2019.

[Multiple Sclerosis in the Emirati Population: Onset Disease Characterization by MR Imaging.](https://www.ncbi.nlm.nih.gov/pubmed/31885922)

Ahmed M, Mir R, Shakra M, Al Fardan S.

Mult Scler Int. 2019 Nov 25;2019:7460213. doi: 10.1155/2019/7460213. eCollection 2019.

[Joint Application of Magnetic Resonance Imaging and Biochemical Biomarkers in Diagnosis of Multiple Sclerosis](https://www.ncbi.nlm.nih.gov/pubmed/31633472)

Momeni F, Ghaemmaghami AB, Nejati M, Pourhanifeh MH, Sichani LS, Tamtaji OR, Momeni M, Khosravi A, Etemadifar M, Mirzaei H.

Curr Med Chem. 2019 Oct 14. doi: 10.2174/0929867326666191014162713. [Epub ahead of print]

[Evaluating optic nerve diameter as a possible biomarker for disability in patients with multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31564882)

Koraysha NA, Kishk N, Hassan A, Samy El Gendy NM, Shehata HS, Al-Azayem SA, Kamal YS.

Neuropsychiatr Dis Treat. 2019 Sep 6;15:2571-2578. doi: 10.2147/NDT.S216079. eCollection 2019.

[Macular ganglion cell complex parameters by optical coherence tomography in cases of multiple sclerosis without optic neuritis compared to healthy eyes.](https://www.ncbi.nlm.nih.gov/pubmed/31007230)

Lotfy NM, Alasbali T, Khandekar R.

Indian J Ophthalmol. 2019 May;67(5):648-653. doi: 10.4103/ijo.IJO\_1378\_18.

**MS Therapies**

[Therapeutic Plasma Exchange in Tehran Between 2011 and 2014.](https://www.ncbi.nlm.nih.gov/pubmed/31177634)

Chegini A, Moghadami M, Maghary AH.

Ther Apher Dial. 2020 Apr;24(2):230-234. doi: 10.1111/1744-9987.12864. Epub 2019 Jul 25.

[Effect of Rituximab on Expanded Disability Status Scale and Relapse Rate in Multiple Sclerosis Patients.](https://www.ncbi.nlm.nih.gov/pubmed/32144724)

Mazdeh M, Khamseh M, Taheri M, Ghafouri-Fard S.

J Mol Neurosci. 2020 Mar 6. doi: 10.1007/s12031-020-01523-w. [Epub ahead of print]

[Enhancing myelin repair in experimental model of multiple sclerosis using immobilized chondroitinase ABC I on porous silicon nanoparticles.](https://www.ncbi.nlm.nih.gov/pubmed/31899243)

Rezaei S, Dabirmanesh B, Zare L, Golestani A, Javan M, Khajeh K.

Int J Biol Macromol. 2020 Mar 1;146:162-170. doi: 10.1016/j.ijbiomac.2019.12.258. Epub 2019 Dec 31.

[Neuroprotective Effects of Melatonin during Demyelination and Remyelination Stages in a Mouse Model of Multiple Sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31713152)

Abo Taleb HA, Alghamdi BS.

J Mol Neurosci. 2020 Mar;70(3):386-402. doi: 10.1007/s12031-019-01425-6. Epub 2019 Nov 11.

[Possible regenerative effects of fingolimod (FTY720) in multiple sclerosis disease: An overview on remyelination process.](https://www.ncbi.nlm.nih.gov/pubmed/31385341)

Yazdi A, Ghasemi-Kasman M, Javan M.

J Neurosci Res. 2020 Mar;98(3):524-536. doi: 10.1002/jnr.24509. Epub 2019 Aug 5. Review.

[The dual reno- and neuro-protective effects of dimethyl fumarate against uremic encephalopathy in a renal ischemia/reperfusion model.](https://www.ncbi.nlm.nih.gov/pubmed/32141026)

Ragab D, Abdallah DM, El-Abhar HS.

Pharmacol Rep. 2020 Mar 5. doi: 10.1007/s43440-020-00076-4.

[Cladribine Tablets and Relapsing-Remitting Multiple Sclerosis: A Pragmatic, Narrative Review of What Physicians Need to Know.](https://www.ncbi.nlm.nih.gov/pubmed/32056129)

AlJumah M, Alkhawajah MM, Qureshi S, Al-Thubaiti I, Ayoub O, Bohlega SA, Bushnag A, Cupler E, Daif A, El Boghdady A, Hassan A, Al Malik Y, Saeedi J, Al-Shamrany F, Shosha E, Rieckmann P.

Neurol Ther. 2020 Feb 13. doi: 10.1007/s40120-020-00177-5. [Epub ahead of print] Review.

[Expert consensus from the Arabian Gulf on selecting disease-modifying treatment for people with multiple sclerosis according to disease activity.](https://www.ncbi.nlm.nih.gov/pubmed/32089038)

Alroughani R, Inshasi J, Al-Asmi A, Alqallaf A, Al Salti A, Shatila A, Boshra A, Canibano B, Deleu D, Al Sharoqi I, Al Khabouri J.

Postgrad Med. 2020 Feb 28:1-9. doi: 10.1080/00325481.2020.1734394.

[Fingolimod for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.](https://www.ncbi.nlm.nih.gov/pubmed/32106137)

Algahtani H, Shirah B, Al Malik Y, Meftah I.

Clin Neuropharmacol. 2020 Feb 26. doi: 10.1097/WNF.0000000000000378. [Epub ahead of print]

[Glatiramer acetate attenuates renal ischemia reperfusion injury in rat model.](https://www.ncbi.nlm.nih.gov/pubmed/31697931)

Nezamoleslami S, Sheibani M, Dehpour AR, Mobasheran P, Shafaroodi H.

Exp Mol Pathol. 2020 Feb;112:104329. doi: 10.1016/j.yexmp.2019.104329. Epub 2019 Nov 4.

[Intranasal delivery of SDF-1α-preconditioned bone marrow mesenchymal cells improves remyelination in the cuprizone-induced mouse model of multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31631484)

Beigi Boroujeni F, Pasbakhsh P, Mortezaee K, Pirhajati V, Alizadeh R, Aryanpour R, Madadi S, Ragerdi Kashani I.

Cell Biol Int. 2020 Feb;44(2):499-511. doi: 10.1002/cbin.11250. Epub 2019 Nov 1.

[Management of relapsing-remitting multiple sclerosis in Qatar: an expert consensus.](https://www.ncbi.nlm.nih.gov/pubmed/31530036)

Deleu D, Canibaño B, Mesraoua B, Adeli G, Abdelmoneim MS, Ali Y, Elalamy O, Melikyan G, Boshra A.

Curr Med Res Opin. 2020 Feb;36(2):251-260. doi: 10.1080/03007995.2019.1669378. Epub 2019 Oct 7.

[Necrotizing fungal osteomyelitis and fingolimod, 4 years after treatment with fingolimod.](https://www.ncbi.nlm.nih.gov/pubmed/32126512)

Harirchian MH, Poursadeghfard M, Sadeghipour A, Kamali H, Sarraf P.

Mult Scler Relat Disord. 2020 Feb 22;41:102021. doi: 10.1016/j.msard.2020.102021. [Epub ahead of print]

[The effects and side effects of laquinimod for the treatment of multiple sclerosis patients: a systematic review and meta-analysis of clinical trials.](https://www.ncbi.nlm.nih.gov/pubmed/32020320)

Rouhi F, Mohammadpour Z, Noureini SK, Abbastabar H, Harirchian MH, Bitarafan S.

Eur J Clin Pharmacol. 2020 Feb 4. doi: 10.1007/s00228-019-02827-6. [Epub ahead of print] Review.

[Incidence of seroconversion and sero-reversion in patients with multiple sclerosis (MS) who had been treated with natalizumab: A systematic review and meta-analysis.](https://www.ncbi.nlm.nih.gov/pubmed/31558363)

Azimi A, Hanaei S, Sahraian MA, Mohammadifar M, Ramagopalan SV, Ghajarzadeh M.

J Clin Neurosci. 2020 Jan;71:129-134. doi: 10.1016/j.jocn.2019.08.103. Epub 2019 Sep 23.

[Mesenchymal stem cells as a treatment for multiple sclerosis: a focus on experimental animal studies.](https://www.ncbi.nlm.nih.gov/pubmed/31605598)

Lotfy A, Ali NS, Abdelgawad M, Salama M.

Rev Neurosci. 2020 Jan 28;31(2):161-179. doi: 10.1515/revneuro-2019-0040.

[Treatment of multiple sclerosis in special populations: The case of refugees.](https://www.ncbi.nlm.nih.gov/pubmed/31976080)

Zeineddine MM, Yamout BI.

Mult Scler J Exp Transl Clin. 2020 Jan 9;6(1):2055217319848466. doi: 10.1177/2055217319848466. eCollection 2020 Jan-Mar.

[Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?](https://www.ncbi.nlm.nih.gov/pubmed/31313222)

Rivera VM.

Neurol Ther. 2019 Dec;8(2):177-184. doi: 10.1007/s40120-019-0145-0. Epub 2019 Jul 16.

[Cortical Excitability Measures May Predict Clinical Response to Fampridine in Patients with Multiple Sclerosis and Gait Impairment.](https://www.ncbi.nlm.nih.gov/pubmed/31817319)

Ahdab R, Shatila MM, Shatila AR, Khazen G, Freiha J, Salem M, Makhoul K, El Nawar R, El Nemr S, Ayache SS, Riachi N.

Brain Sci. 2019 Dec 5;9(12). pii: E357. doi: 10.3390/brainsci9120357

[Impact of opium dependency on clinical and neuropsychological indices of multiple sclerosis patients.](https://www.ncbi.nlm.nih.gov/pubmed/31264108)

Ayoobi F, Bidaki R, Shamsizadeh A, Moghadam-Ahmadi A, Amiri H.

Neurol Sci. 2019 Dec;40(12):2501-2507. doi: 10.1007/s10072-019-03971-8. Epub 2019 Jul 1.

[Late Cardiotoxicity in MS Patients Treated with Mitoxantrone.](https://www.ncbi.nlm.nih.gov/pubmed/31921403)

Najafian J, Nasri A, Etemadifar M, Salehzadeh F.

Int J Prev Med. 2019 Dec 10;10:211. doi: 10.4103/ijpvm.IJPVM\_477\_17. eCollection 2019.

[Simvastatin Therapy in Multiple Sclerosis Patients with Respect to Gut Microbiome-Friend or Foe?](https://www.ncbi.nlm.nih.gov/pubmed/31628587)

Toghi M, Bitarafan S.

J Neuroimmune Pharmacol. 2019 Dec;14(4):531-533. doi: 10.1007/s11481-019-09881-y. Epub 2019 Oct 18. No abstract available.

[Safety and efficacy of stem cell therapy for treatment of neural damage in patients with multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/32039266)

Jafarzadeh Bejargafshe M, Hedayati M, Zahabiasli S, Tahmasbpour E, Rahmanzadeh S, Nejad-Moghaddam A.

Stem Cell Investig. 2019 Dec 27;6:44. doi: 10.21037/sci.2019.10.06. eCollection 2019. Review.

[The effects of vitamin D supplementation on expanded disability status scale in people with multiple sclerosis: A critical, systematic review and metaanalysis of randomized controlled trials.](https://www.ncbi.nlm.nih.gov/pubmed/31669929)

Doosti-Irani A, Tamtaji OR, Mansournia MA, Ghayour-Mobarhan M, Ferns G, Daneshvar Kakhaki R, Rezaei Shahmirzadi A, Asemi Z.

Clin Neurol Neurosurg. 2019 Dec;187:105564. doi: 10.1016/j.clineuro.2019.105564. Epub 2019 Oct 14. Review.

[Tumefactive rebound of multiple sclerosis after the short-term cessation of fingolimod: A case report.](https://www.ncbi.nlm.nih.gov/pubmed/31862655)

Ashtari F, Sahraian MA, Oustad M, Nilipour Y.

Mult Scler Relat Disord. 2019 Dec 6;39:101883. doi: 10.1016/j.msard.2019.101883. [Epub ahead of print]

[Assessment of safety and effectiveness of oral multiple sclerosis medication.](https://www.ncbi.nlm.nih.gov/pubmed/31707408)

Al Turaiki AM, Al Ammari MA, Alabdulkarim DA, Althemery AU.

Saudi Med J. 2019 Nov;40(11):1116-1122. doi: 10.15537/smj.2019.11.24630.

[Evaluating the efficacy and safety of ZytuxTM (Rituximab, AryoGen pharmed) in Iranian multiple sclerosis patients: An observational study.](https://www.ncbi.nlm.nih.gov/pubmed/31586800)

Naser Moghadasi A, Darki A, Masoumi P, Hashemi SN, Ghadiri F.

Mult Scler Relat Disord. 2019 Nov;36:101419. doi: 10.1016/j.msard.2019.101419. Epub 2019 Sep 27.

[Immunomodulatory and anti-inflammatory effects of probiotics in multiple sclerosis: a systematic review.](https://www.ncbi.nlm.nih.gov/pubmed/31752913)

Morshedi M, Hashemi R, Moazzen S, Sahebkar A, Hosseinifard ES.

J Neuroinflammation. 2019 Nov 21;16(1):231. doi: 10.1186/s12974-019-1611-4. Review.

[Severe rebound disease activity after fingolimod withdrawal in a pregnant woman with multiple sclerosis managed with rituximab: A case study.](https://www.ncbi.nlm.nih.gov/pubmed/31867224)

Canibaño B, Ali M, Mesraoua B, Melikyan G, Al Hail H, Ibrahim F, Hanssens Y, Deleu D.

Case Rep Womens Health. 2019 Nov 20;25:e00162. doi: 10.1016/j.crwh.2019.e00162. eCollection 2020 Jan.

[Skin warts during fingolimod treatment in patients with multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31606603)

Jaafar N, Zeineddine M, Massouh J, Yamout BI.

Mult Scler Relat Disord. 2019 Nov;36:101437. doi: 10.1016/j.msard.2019.101437. Epub 2019 Oct 7.

[The potentials of umbilical cord-derived mesenchymal stem cells in the treatment of multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31026226)

Mehdipour A, Ebrahimi A, Shiri-Shahsavar MR, Soleimani-Rad J, Roshangar L, Samiei M, Ebrahimi-Kalan A.

Rev Neurosci. 2019 Nov 26;30(8):857-868. doi: 10.1515/revneuro-2018-0057.

[Bullous pemphigoid as an injection site reaction of glatiramer acetate.](https://www.ncbi.nlm.nih.gov/pubmed/32117558)

Baghbanian SM, Ghasemi M, Sheidaei S, Hajheydari Z.

Iran J Neurol. 2019 Oct 7;18(4):187-189. No abstract available.

# Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines.

[Yamout B](https://www.ncbi.nlm.nih.gov/pubmed/?term=Yamout%20B%5BAuthor%5D&cauthor=true&cauthor_uid=31670208), [Sahraian M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sahraian%20M%5BAuthor%5D&cauthor=true&cauthor_uid=31670208), [Bohlega S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bohlega%20S%5BAuthor%5D&cauthor=true&cauthor_uid=31670208), [Al-Jumah M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Al-Jumah%20M%5BAuthor%5D&cauthor=true&cauthor_uid=31670208), [Goueider R](https://www.ncbi.nlm.nih.gov/pubmed/?term=Goueider%20R%5BAuthor%5D&cauthor=true&cauthor_uid=31670208), [Dahdaleh M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Dahdaleh%20M%5BAuthor%5D&cauthor=true&cauthor_uid=31670208), [Inshasi J](https://www.ncbi.nlm.nih.gov/pubmed/?term=Inshasi%20J%5BAuthor%5D&cauthor=true&cauthor_uid=31670208), [Hashem S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Hashem%20S%5BAuthor%5D&cauthor=true&cauthor_uid=31670208), [Alsharoqi I](https://www.ncbi.nlm.nih.gov/pubmed/?term=Alsharoqi%20I%5BAuthor%5D&cauthor=true&cauthor_uid=31670208), [Khoury S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Khoury%20S%5BAuthor%5D&cauthor=true&cauthor_uid=31670208), [Alkhawajah M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Alkhawajah%20M%5BAuthor%5D&cauthor=true&cauthor_uid=31670208), [Koussa S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Koussa%20S%5BAuthor%5D&cauthor=true&cauthor_uid=31670208), [Al Khaburi J](https://www.ncbi.nlm.nih.gov/pubmed/?term=Al%20Khaburi%20J%5BAuthor%5D&cauthor=true&cauthor_uid=31670208), [Almahdawi A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Almahdawi%20A%5BAuthor%5D&cauthor=true&cauthor_uid=31670208), [Alsaadi T](https://www.ncbi.nlm.nih.gov/pubmed/?term=Alsaadi%20T%5BAuthor%5D&cauthor=true&cauthor_uid=31670208), [Slassi E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Slassi%20E%5BAuthor%5D&cauthor=true&cauthor_uid=31670208), [Daodi S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Daodi%20S%5BAuthor%5D&cauthor=true&cauthor_uid=31670208), [Zakaria M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Zakaria%20M%5BAuthor%5D&cauthor=true&cauthor_uid=31670208), [Alroughani R](https://www.ncbi.nlm.nih.gov/pubmed/?term=Alroughani%20R%5BAuthor%5D&cauthor=true&cauthor_uid=31670208)

[Mult Scler Relat Disord.](https://www.ncbi.nlm.nih.gov/pubmed/31670208) 2019 Oct 18;37:101459. doi: 10.1016/j.msard.2019.101459.

[Effectiveness and side effects of dimethyl fumarate in multiple sclerosis after 12 months of follow up: An Iranian clinical trial.](https://www.ncbi.nlm.nih.gov/pubmed/32117551)

Foroughipour M, Gazeran S.

Iran J Neurol. 2019 Oct 7;18(4):154-158.

[The potential use of mesenchymal stem cells for the treatment of multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31487529)

Mansoor SR, Zabihi E, Ghasemi-Kasman M.

Life Sci. 2019 Oct 15;235:116830. doi: 10.1016/j.lfs.2019.116830. Epub 2019 Sep 2. Review.

[Tumefactive demyelinating lesions after initiating fingolimod in patient with multiple sclerosis: A case report.](https://www.ncbi.nlm.nih.gov/pubmed/31668286)

Navardi S, Sahraian MA, Naser Moghadasi A.

Rev Neurol (Paris). 2019 Oct 23. pii: S0035-3787(19)30639-3. doi: 10.1016/j.neurol.2019.08.008. [Epub ahead of print] No abstract available.

[Long term effects of corticosteroids in multiple sclerosis in terms of the "no evidence of disease activity" (NEDA) domains.](https://www.ncbi.nlm.nih.gov/pubmed/31100292)

Saied A, Elsaid N, Azab A.

Steroids. 2019 Sep;149:108401. doi: 10.1016/j.steroids.2019.04.006. Epub 2019 May 15.

[Combination therapy with interferon beta-1a and sesame oil in multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31331574)

Faraji F, Hashemi M, Ghiasabadi A, Davoudian S, Talaie A, Ganji A, Mosayebi G.

Complement Ther Med. 2019 Aug;45:275-279. doi: 10.1016/j.ctim.2019.04.010. Epub 2019 Apr 23.

[Curcumin as a therapeutic candidate for multiple sclerosis: Molecular mechanisms and targets.](https://www.ncbi.nlm.nih.gov/pubmed/30536381)

Ghanaatian N, Lashgari NA, Abdolghaffari AH, Rajaee SM, Panahi Y, Barreto GE, Butler AE, Sahebkar A.

J Cell Physiol. 2019 Aug;234(8):12237-12248. doi: 10.1002/jcp.27965. Epub 2018 Dec 10. Review.

[Cutaneous necrotic lesion: A wonderful delay adverse effect of interferon beta-1b injection for multiple sclerosis treatment.](https://www.ncbi.nlm.nih.gov/pubmed/31436377)

Mozafari N, Saffaei A, Alizadeh M, Shabani M.

J Cosmet Dermatol. 2019 Aug 22. doi: 10.1111/jocd.13104. [Epub ahead of print]

[Fingolimod and changes in hematocrit, hemoglobin and red blood cells of patients with multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31497380)

Momeni A, Abrishamkar R, Panahi F, Eslami S, Tavoosi N, Rafiee Zadeh A.

Am J Clin Exp Immunol. 2019 Aug 15;8(4):27-31. eCollection 2019. Retraction in: [Am J Clin Exp Immunol. 2019 Oct 15;8(5):54](https://www.ncbi.nlm.nih.gov/pubmed/31777687).

[Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 2.](https://www.ncbi.nlm.nih.gov/pubmed/31523358)

Rafiee Zadeh A, Ghadimi K, Ataei A, Askari M, Sheikhinia N, Tavoosi N, Falahatian M.

Int J Physiol Pathophysiol Pharmacol. 2019 Aug 15;11(4):105-114. eCollection 2019. Review.

[Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 1.](https://www.ncbi.nlm.nih.gov/pubmed/31523357)

Rafiee Zadeh A, Askari M, Azadani NN, Ataei A, Ghadimi K, Tavoosi N, Falahatian M.

Int J Physiol Pathophysiol Pharmacol. 2019 Aug 15;11(4):95-104. eCollection 2019. Review.

[Neurodevelopmental retardation in a baby born to a multiple sclerosis patient being treated with fingolimod.](https://www.ncbi.nlm.nih.gov/pubmed/31185372)

Cheraghmakani H, Nasehi MM, Baghbanian SM.

Mult Scler Relat Disord. 2019 Aug;33:116-120. doi: 10.1016/j.msard.2019.05.016. Epub 2019 May 30.

[Pharmacokinetics and Bioequivalence Studies of Teriflunomide in Healthy Iranian Volunteers.](https://www.ncbi.nlm.nih.gov/pubmed/31379101)

Rouini MR, Dibaei M, Ghasemian E.

Clin Pharmacol Drug Dev. 2019 Aug 5. doi: 10.1002/cpdd.725. [Epub ahead of print]

[Comparison of the effects of amantadine and ondansetron in treatment of fatigue in patients with multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31263986)

Khazaei M, Karevan A, Taheri M, Ghafouri-Fard S.

Clin Transl Med. 2019 Jul 1;8(1):20. doi: 10.1186/s40169-019-0239-4.

[Exploring the outcome of multiple sclerosis among Saudi adult patients. A single-centered cross-sectional study at King Abdulaziz Medical City in Riyadh, Saudi Arabia.](https://www.ncbi.nlm.nih.gov/pubmed/31380815)

Alanazi AM, Al-Rashoud JR, Aljahani JM, Alotaibi AF, Althubaiti AM, Kojan SM, Aljumah MA, Abulaban AA.

Neurosciences (Riyadh). 2019 Jul;24(3):168-175. doi: 10.17712/nsj.2019.3.20180034.

[GAS8 and its naturally occurring antisense RNA as biomarkers in multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31003831)

Patoughi M, Ghafouri-Fard S, Arsang-Jang S, Taheri M.

Immunobiology. 2019 Jul;224(4):560-564. doi: 10.1016/j.imbio.2019.04.005. Epub 2019 Apr 13.

[Is non-traditional therapy for multiple sclerosis overwhelming in Saudi Arabia.](https://www.ncbi.nlm.nih.gov/pubmed/31380818)

Shariff EM, Al-Shammrani FJ, Nazish S, Zafar AS, Shahid RM, Khuda IE, Zeeshan MA, Alabdali MA, Al-Bakr AI, Aljaafari DT, Balharith IO, Alahmed AA, Alsalman SA, Almajed AM, Alkhamis FA.

Neurosciences (Riyadh). 2019 Jul;24(3):192-198. doi: 10.17712/nsj.2019.3.20180010.

[Melatonin and Multiple Sclerosis: From Plausible Neuropharmacological Mechanisms of Action to Experimental and Clinical Evidence.](https://www.ncbi.nlm.nih.gov/pubmed/31054087)

Yeganeh Salehpour M, Mollica A, Momtaz S, Sanadgol N, Farzaei MH.

Clin Drug Investig. 2019 Jul;39(7):607-624. doi: 10.1007/s40261-019-00793-6. Review.

[An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion.](https://www.ncbi.nlm.nih.gov/pubmed/30875021)

Alroughani R, Inshasi JS, Deleu D, Al-Hashel J, Shakra M, Elalamy OR, Shatila AO, Al-Asmi A, Al Sharoqi I, Canibano BG, Boshra A.

Neurol Ther. 2019 Jun;8(1):13-23

[Curcumin-loaded nanoparticles: a novel therapeutic strategy in treatment of central nervous system disorders.](https://www.ncbi.nlm.nih.gov/pubmed/31417253)

Yavarpour-Bali H, Ghasemi-Kasman M, Pirzadeh M.

Int J Nanomedicine. 2019 Jun 17;14:4449-4460. doi: 10.2147/IJN.S208332. eCollection 2019. Review.

[Interferon β-induced acute pancreatitis: About two cases with literature review.](https://www.ncbi.nlm.nih.gov/pubmed/30665738)

Aouinti I, Hamza I, Charfi O, Lakhoua G, El Aidli S, Daghfous R, Zaiem A, Kastalli S.

Therapie. 2019 Jun;74(3):449-450. doi: 10.1016/j.therap.2018.12.006. Epub 2019 Jan 2. No abstract available.

[The effects of probiotic Saccharomyces boulardii on the mental health, quality of life, fatigue, pain, and indices of inflammation and oxidative stress in patients with multiple sclerosis: study protocol for a double-blind randomized controlled clinical trial.](https://www.ncbi.nlm.nih.gov/pubmed/31234904)

Aghamohammadi D, Ayromlou H, Dolatkhah N, Jahanjoo F, Shakouri SK.

Trials. 2019 Jun 24;20(1):379. doi: 10.1186/s13063-019-3454-9.

[MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31072380)

Uccelli A, Laroni A, Brundin L, Clanet M, Fernandez O, Nabavi SM, Muraro PA, Oliveri RS, Radue EW, Sellner J, Soelberg Sorensen P, Sormani MP, Wuerfel JT, Battaglia MA, Freedman MS; MESEMS study group.

Trials. 2019 May 9;20(1):263. doi: 10.1186/s13063-019-3346-z.

**Pediatric MS**

[Pediatric multiple sclerosis and its familial recurrence: A population based study (1999-2017).](https://www.ncbi.nlm.nih.gov/pubmed/31473489)

Eskandarieh S, Sahraiain MA, Molazadeh N, Moghadasi AN.

Mult Scler Relat Disord. 2019 Nov;36:101377. doi: 10.1016/j.msard.2019.101377. Epub 2019 Aug 27.

**Others**

['I want to be with you, but I have MS': Challenges of interpersonal relationships from the MS patients' point of view.](https://www.ncbi.nlm.nih.gov/pubmed/32017315)

Sharifi M, Neshat Doost HT, Shayegannejad V.

Health Soc Care Community. 2020 Feb 4. doi: 10.1111/hsc.12936

[Multiple cause of death analysis in multiple sclerosis: A population-based study.](https://www.ncbi.nlm.nih.gov/pubmed/31932517)

Harding K, Zhu F, Alotaibi M, Duggan T, Tremlett H, Kingwell E.

Neurology. 2020 Feb 25;94(8):e820-e829. doi: 10.1212/WNL.0000000000008907. Epub 2020 Jan 13.

[Psychometric properties of an Arabic translation of the modified fatigue impact scale in patients with multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/32109166)

Alawami AS, Abdulla FA.

Disabil Rehabil. 2020 Feb 28:1-9. doi: 10.1080/09638288.2020.1731853. [Epub ahead of print]

[Serum vitamin D level is associated with speed of processing in multiple sclerosis patients.](https://www.ncbi.nlm.nih.gov/pubmed/32061642)

Darwish H, Farran N, Hannoun S, Tadros N, Yamout B, El Ayoubi NK, Khoury SJ.

J Steroid Biochem Mol Biol. 2020 Feb 19;200:105628. doi: 10.1016/j.jsbmb.2020.105628. [Epub ahead of print]

[Staphylococcal enterotoxin B increased severity of experimental model of multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/32061822)

Pakbaz Z, Sahraian MA, Noorbakhsh F, Salami SA, Pourmand MR.

Microb Pathog. 2020 Feb 18;142:104064. doi: 10.1016/j.micpath.2020.104064. [Epub ahead of print]

[The therapeutic effect of treatment with RehaCom software on verbal performance in patients with multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31937503)

Arian Darestani A, Naeeni Davarani M, Hassani-Abharian P, Zarrindast MR, Nasehi M.

J Clin Neurosci. 2020 Feb;72:93-97. doi: 10.1016/j.jocn.2020.01.007. Epub 2020 Jan 11.

[Transbulbar B-mode sonography in multiple sclerosis without optic neuritis; clinical relevance.](https://www.ncbi.nlm.nih.gov/pubmed/32057807)

Raeesmohammadi L, Esmaeili S, Abbasi MH, Mehrpour M, Mirzaasgari Z, Baradaran HR, Deilami P, Motamed MR.

Brain Res. 2020 Feb 11;1734:146723. doi: 10.1016/j.brainres.2020.146723. [Epub ahead of print]

[The Multiple Sclerosis Self-Management Scale-Revised (MSSM-R): Persian Version and Psychometric Analysis.](https://www.ncbi.nlm.nih.gov/pubmed/32123527)

Saadat S, Kajbaf MB, Kalantari M, Hosseininezhad M.

Int J MS Care. 2020 Jan-Feb;22(1):37-42. doi: 10.7224/1537-2073.2018-090.

[Assessment of the Burden of Multiple Sclerosis Patients' Caregivers in Saudi Arabia.](https://www.ncbi.nlm.nih.gov/pubmed/31966949)

Algahtani H, Shirah B, Bayazeed A, Alghamdi A, Almailabi M, Algharib M, Alkahtani F.

Cureus. 2020 Jan 14;12(1):e6658. doi: 10.7759/cureus.6658.

[Concurrence of multiple sclerosis, oligodendroglioma, and autosomal recessive cerebellar ataxia with spasticity in the same patient: A challenging diagnosis.](https://www.ncbi.nlm.nih.gov/pubmed/31954225)

Algahtani H, Shirah B, Tashkandi M, Samkari A.

Mult Scler Relat Disord. 2020 Jan 11;40:101945. doi: 10.1016/j.msard.2020.101945. [Epub ahead of print]

[Combined virtual reality and physical training improved the bimanual coordination of women with multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31971071)

Norouzi E, Gerber M, Pühse U, Vaezmosavi M, Brand S.

Neuropsychol Rehabil. 2020 Jan 23:1-18. doi: 10.1080/09602011.2020.1715231. [Epub ahead of print]

[Factors affecting MS patients' health-related quality of life and measurement challenges in Lebanon and the MENA region.](https://www.ncbi.nlm.nih.gov/pubmed/31976081)

Farran N, Safieddine BR, Bayram M, Abi Hanna T, Massouh J, AlKhawaja M, Tamim H, Darwish H.

Mult Scler J Exp Transl Clin. 2020 Jan 9;6(1):2055217319848467. doi: 10.1177/2055217319848467.

[Family-centred empowerment program for health literacy and self-efficacy in family caregivers of patients with multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31985862)

Jafari Y, Tehrani H, Esmaily H, Shariati M, Vahedian-Shahroodi M.

Scand J Caring Sci. 2020 Jan 27. doi: 10.1111/scs.12803. [Epub ahead of print]

[Persian Adaptation of Actionable Bladder Symptom Screening Tool Among Patients with Multiple Sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/32021237)

Azadvari M, Naser Moghadasi A, Azimi AR, Sharifiaghdas F, Emami Razavi SZ, Eskandarieh S, Hosseini M, Rahimi-Dehgolan S, Sahraian MA.

J Multidiscip Healthc. 2020 Jan 17;13:79-83. doi: 10.2147/JMDH.S236275. eCollection 2020.

[Orem's Self-Care Model with Multiple Sclerosis Patients' Balance and Motor Function.](https://www.ncbi.nlm.nih.gov/pubmed/31795883)

Afrasiabifar A, Mehri Z, Ghaffarian Shirazi HR.

Nurs Sci Q. 2020 Jan;33(1):46-54. doi: 10.1177/0894318419881792.

[Psychometric properties of the Arabic Activities-specific Balance Confidence scale in people with multiple sclerosis: Reliability, validity, and minimal detectable change.](https://www.ncbi.nlm.nih.gov/pubmed/32039869)

Alghwiri AA, Khalil H, Al-Sharman A, El-Salem K.

NeuroRehabilitation. 2020;46(1):119-125. doi: 10.3233/NRE-192900.

[Trans-orbital sonography versus visual evoked potentials in acute demyelinating optic neuritis.](https://www.ncbi.nlm.nih.gov/pubmed/31986426)

Elkholy SH, El-Jaafary SI, Kotb MS, El Gohary AM, Elbhy BA.

Mult Scler Relat Disord. 2020 Jan 15;40:101934. doi: 10.1016/j.msard.2020

[Association of infections with multiple sclerosis in Gulf Cooperation Council countries: a review.](https://www.ncbi.nlm.nih.gov/pubmed/31880177)

Al Wutayd O.

J Int Med Res. 2019 Dec 27:300060519884151. doi: 10.1177/0300060519884151.

[Evaluation of cognitive rehabilitation on the cognitive performance in multiple sclerosis: A randomized controlled trial.](https://www.ncbi.nlm.nih.gov/pubmed/31949461)

Shahpouri MM, Barekatain M, Tavakoli M, Sanaei S, Shaygannejad V.

J Res Med Sci. 2019 Dec 23;24:110. doi: 10.4103/jrms.JRMS\_124\_19. eCollection 2019.

[Naming error in multiple sclerosis patients: A pilot study in Isfahan, Iran.](https://www.ncbi.nlm.nih.gov/pubmed/31949456)

Shamsian F, Dastjerdi RM, Kavosh A, Ashtari F.

J Res Med Sci. 2019 Dec 23;24:105. doi: 10.4103/jrms.JRMS\_497\_18. eCollection 2019.

[SCC*mec* Genotypes of Methicillin-Resistant *Staphylococcus aureus* in Nasal Carriage of Multiple Sclerosis Patients in Iran.](https://www.ncbi.nlm.nih.gov/pubmed/31993396)

Jamshidi Y, Pourmand MR, Pakbaz Z, Pourmand A, Rahimi Foroushani A, Sahraian MA.

Iran J Public Health. 2019 Dec;48(12):2270-2276.

[Cross cultural adaptation and psychometric evaluation of an Arabic version of the modified fatigue impact scale in people with multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31841967)

Khalil H, Al-Shorman A, Alghwiri AA, Abdo N, El-Salem K, Shalabi S, Aburub A.

Mult Scler Relat Disord. 2019 Nov 29;39:101878. doi: 10.1016/j.msard.2019.101878. [Epub ahead of print]

[The effects of aerobic exercise on sleep quality measures and sleep-related biomarkers in individuals with Multiple Sclerosis: A pilot randomised controlled trial.](https://www.ncbi.nlm.nih.gov/pubmed/31403958)

Al-Sharman A, Khalil H, El-Salem K, Aldughmi M, Aburub A.

NeuroRehabilitation. 2019;45(1):107-115. doi: 10.3233/NRE-192748.

[Assessment of the complementary and integrative medicine utilization among patients with multiple sclerosis using a translated and adapted version of the international questionnaire (I-CAM-QP): A cross-sectional study in Southern Iran.](https://www.ncbi.nlm.nih.gov/pubmed/31519287)

Farhoudi F, Salehi A, Vojoud M, Molavi Vardanjani H.

Complement Ther Med. 2019 Oct;46:47-53. doi: 10.1016/j.ctim.2019.07.016. Epub 2019 Jul 24.

[Awareness of patients with multiple sclerosis in Saudi Arabia regarding the relationship between smoking and multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31872806)

Bashamakh LF, Alsharif SM, Wayyani LA, Alghamdi AE, Fatani GM, Alnajashi HA, Alshamrani FJ.

Neurosciences (Riyadh). 2019 Oct;24(4):278-283. doi: 10.17712/nsj.2019.4.20190027.

[Comparison of Food Intake in Multiple Sclerosis Patients and Healthy Individuals: A Hospital-Based Case-Controlled Study.](https://www.ncbi.nlm.nih.gov/pubmed/31645874)

Ghazavi Y, Bahadoran Z, Nikfarjam M, Moghaddam NB, Mirmiran P, Heydari MR.

Iran J Child Neurol. 2019 Fall;13(4):143-154.

["Disability Grief": A patient's allegorical expression of her disability.](https://www.ncbi.nlm.nih.gov/pubmed/32117559)

Moghadasi AN.

Iran J Neurol. 2019 Oct 7;18(4):190-191. No abstract available.

[Effects of Death Anxiety on Perceived Stress in Individuals With Multiple Sclerosis and the Role of Self-Transcendence.](https://www.ncbi.nlm.nih.gov/pubmed/31584337)

Abdollahi A, Panahipour H, Allen KA, Hosseinian S.

Omega (Westport). 2019 Oct 4:30222819880714. doi: 10.1177/0030222819880714. [Epub ahead of print] No abstract available.

[Motor performance improvement through virtual reality task is related to fatigue and cognition in people with multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31120581)

Al-Sharman A, Khalil H, El-Salem K, Alghwiri AA, Khazaaleh S, Khraim M.

Physiother Res Int. 2019 Oct;24(4):e1782. doi: 10.1002/pri.1782. Epub 2019 May 23.

[Multiple Sclerosis Patients Knowledge in Saudi Arabia.](https://www.ncbi.nlm.nih.gov/pubmed/31872816)

Abulaban A, Altowairqi A, Altowairqi H, Almutairi A, Altalhi S, Alotaibi F, Alabbadi I.

Neurosciences (Riyadh). 2019 Oct;24(4):327-330. doi: 10.17712/nsj.2019.4.20190031.

[Mechanisms of pathophysiology of blood vessels in patients with multiple sclerosis treated with ozone therapy: a systematic review.](https://www.ncbi.nlm.nih.gov/pubmed/31580307)

Ameli J, Banki A, Khorvash F, Simonetti V, Jafari NJ, Izadi M.

Acta Biomed. 2019 Sep 6;90(3):213-217. doi: 10.23750/abm.v90i3.7265.

[Motor reaction time and accuracy in patients with multiple sclerosis: effects of an active computerized training program.](https://www.ncbi.nlm.nih.gov/pubmed/31055729)

Dana A, Rafiee S, Gholami A.

Neurol Sci. 2019 Sep;40(9):1849-1854. doi: 10.1007/s10072-019-03892-6. Epub 2019 May 4.

[Sirtuins in Multiple Sclerosis: The crossroad of neurodegeneration, autoimmunity and metabolism.](https://www.ncbi.nlm.nih.gov/pubmed/31228716)

Foolad F, Khodagholi F, Javan M.

Mult Scler Relat Disord. 2019 Sep;34:47-58. doi: 10.1016/j.msard.2019.06.004. Epub 2019 Jun 9. Review.

[Effect of omega-3 fatty acids and fish oil supplementation on multiple sclerosis: a systematic review.](https://www.ncbi.nlm.nih.gov/pubmed/31462182)

AlAmmar WA, Albeesh FH, Ibrahim LM, Algindan YY, Yamani LZ, Khattab RY.

Nutr Neurosci. 2019 Aug 28:1-11. doi: 10.1080/1028415X.2019.1659560. [Epub ahead of print]

[Psychometric properties of the Persian-version of the Activities-specific Balance Confidence scale and Fall Efficacy Scale-International in Iranian patients with multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31455119)

Monjezi S, Negahban H, Tajali S, Mofateh R, Molhemi F, Mostafaee N.

Physiother Theory Pract. 2019 Aug 27:1-10. doi: 10.1080/09593985.2019.1658247. [Epub ahead of print]

[Factors Involved in Relapse of Multiple Sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31548920)

Kamel FO.

J Microsc Ultrastruct. 2019 Jul-Sep;7(3):103-108. doi: 10.4103/JMAU.JMAU\_59\_18. Review.

[A comparative study of uncertainty and coping strategies of patients with multiple sclerosis for members and nonmembers in peer groups.](https://www.ncbi.nlm.nih.gov/pubmed/31259667)

Biglar Chopoghlou S, Hanifi N, Varjoshani NJ.

Health Care Women Int. 2019 Jul 1:1-14. doi: 10.1080/07399332.2019.1621317.

[Challenges in the Daily Living Activities of Patients with Multiple Sclerosis: A Qualitative Content Analysis.](https://www.ncbi.nlm.nih.gov/pubmed/31341919)

Dehghani A, Khoramkish M, Shahsavari Isfahani S.

Int J Community Based Nurs Midwifery. 2019 Jul;7(3):201-210. doi: 10.30476/IJCBNM.2019.44995.

[Whole body vibration improves core muscle strength and endurance in ambulant individuals with multiple sclerosis: A randomized clinical trial.](https://www.ncbi.nlm.nih.gov/pubmed/31071658)

Abbasi M, Kordi Yoosefinejad A, Poursadeghfard M, Parsaei Jahromi F, Motealleh A, Sobhani S.

Mult Scler Relat Disord. 2019 Jul;32:88-93. doi: 10.1016/j.msard.2019.04.028. Epub 2019 Apr 30.

[Impaired local dynamic stability during treadmill walking predicts future falls in patients with multiple sclerosis: A prospective cohort study.](https://www.ncbi.nlm.nih.gov/pubmed/31234121)

Tajali S, Mehravar M, Negahban H, van Dieën JH, Shaterzadeh-Yazdi MJ, Mofateh R.

Clin Biomech (Bristol, Avon). 2019 Jul;67:197-201. doi: 10.1016/j.clinbiomech.2019.05.013. Epub 2019 May 9.

[Relationship between the use of electronic devices and susceptibility to multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31168332)

Khaki-Khatibi F, Nourazarian A, Ahmadi F, Farhoudi M, Savadi-Oskouei D, Pourostadi M, Asgharzadeh M.

Cogn Neurodyn. 2019 Jun;13(3):287-292. doi: 10.1007/s11571-019-09524-1. Epub 2019 Feb 2.

[Validation of the Persian version of the dysphagia in multiple sclerosis questionnaire for the assessment of dysphagia in multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31333731)

Asadollahpour F, Mehri A, Khatoonabadi A, Mohammadzaheri F, Ebadi A.

J Res Med Sci. 2019 Jun 25;24:52. doi: 10.4103/jrms.JRMS\_248\_18. eCollection 2019.

[Economic burden of multiple sclerosis on Kuwait health care system.](https://www.ncbi.nlm.nih.gov/pubmed/31086393)

Alowayesh MS, Ahmed SF, Al-Hashel J, Alroughani R.

PLoS One. 2019 May 14;14(5):e0216646.

[Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in people with multiple sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/31150100)

Jagannath VA, Pucci E, Asokan GV, Robak EW.

Cochrane Database Syst Rev. 2019 May 31;5:CD009903